197 related articles for article (PubMed ID: 25071006)
1. FANCD2 re-expression is associated with glioma grade and chemical inhibition of the Fanconi Anaemia pathway sensitises gliomas to chemotherapeutic agents.
Patil AA; Sayal P; Depondt ML; Beveridge RD; Roylance A; Kriplani DH; Myers KN; Cox A; Jellinek D; Fernando M; Carroll TA; Collis SJ
Oncotarget; 2014 Aug; 5(15):6414-24. PubMed ID: 25071006
[TBL] [Abstract][Full Text] [Related]
2. The Fanconi anemia (FA) pathway confers glioma resistance to DNA alkylating agents.
Chen CC; Taniguchi T; D'Andrea A
J Mol Med (Berl); 2007 May; 85(5):497-509. PubMed ID: 17221219
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of DNA-repair genes Ercc1 and Mgmt enhances temozolomide efficacy in gliomas treatment: a pre-clinical study.
Boccard SG; Marand SV; Geraci S; Pycroft L; Berger FR; Pelletier LA
Oncotarget; 2015 Oct; 6(30):29456-68. PubMed ID: 26336131
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of elongation factor-2 kinase augments the antitumor activity of Temozolomide against glioma.
Liu XY; Zhang L; Wu J; Zhou L; Ren YJ; Yang WQ; Ming ZJ; Chen B; Wang J; Zhang Y; Yang JM
PLoS One; 2013; 8(11):e81345. PubMed ID: 24303044
[TBL] [Abstract][Full Text] [Related]
5. Rad51 inhibition is an effective means of targeting DNA repair in glioma models and CD133+ tumor-derived cells.
Short SC; Giampieri S; Worku M; Alcaide-German M; Sioftanos G; Bourne S; Lio KI; Shaked-Rabi M; Martindale C
Neuro Oncol; 2011 May; 13(5):487-99. PubMed ID: 21363882
[TBL] [Abstract][Full Text] [Related]
6. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
[TBL] [Abstract][Full Text] [Related]
7. Differential expression of miR200a-3p and miR21 in grade II-III and grade IV gliomas: evidence that miR200a-3p is regulated by O⁶-methylguanine methyltransferase and promotes temozolomide responsiveness.
Berthois Y; Delfino C; Metellus P; Fina F; Nanni-Metellus I; Al Aswy H; Pirisi V; Ouafik L; Boudouresque F
Cancer Biol Ther; 2014 Jul; 15(7):938-50. PubMed ID: 24755707
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of BRCA1-BRCA2-containing complex subunit 3 sensitizes glioma cells to temozolomide.
Chai KM; Wang CY; Liaw HJ; Fang KM; Yang CS; Tzeng SF
Oncotarget; 2014 Nov; 5(21):10901-15. PubMed ID: 25337721
[TBL] [Abstract][Full Text] [Related]
9. Poly(ADP-ribose) polymerase inhibitor increases growth inhibition and reduces G(2)/M cell accumulation induced by temozolomide in malignant glioma cells.
Tentori L; Portarena I; Torino F; Scerrati M; Navarra P; Graziani G
Glia; 2002 Oct; 40(1):44-54. PubMed ID: 12237842
[TBL] [Abstract][Full Text] [Related]
10. A novel drug conjugate, NEO212, targeting proneural and mesenchymal subtypes of patient-derived glioma cancer stem cells.
Jhaveri N; Agasse F; Armstrong D; Peng L; Commins D; Wang W; Rosenstein-Sisson R; Vaikari VP; Santiago SV; Santos T; Chen L; Schönthal AH; Chen TC; Hofman FM
Cancer Lett; 2016 Feb; 371(2):240-50. PubMed ID: 26683773
[TBL] [Abstract][Full Text] [Related]
11. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
[TBL] [Abstract][Full Text] [Related]
12. Exogenous IGFBP-2 promotes proliferation, invasion, and chemoresistance to temozolomide in glioma cells via the integrin β1-ERK pathway.
Han S; Li Z; Master LM; Master ZW; Wu A
Br J Cancer; 2014 Sep; 111(7):1400-9. PubMed ID: 25093489
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of prolyl 4-hydroxylase, beta polypeptide (P4HB) attenuates temozolomide resistance in malignant glioma via the endoplasmic reticulum stress response (ERSR) pathways.
Sun S; Lee D; Ho AS; Pu JK; Zhang XQ; Lee NP; Day PJ; Lui WM; Fung CF; Leung GK
Neuro Oncol; 2013 May; 15(5):562-77. PubMed ID: 23444257
[TBL] [Abstract][Full Text] [Related]
14. Targeting the Fanconi anemia/BRCA pathway circumvents drug resistance in multiple myeloma.
Yarde DN; Oliveira V; Mathews L; Wang X; Villagra A; Boulware D; Shain KH; Hazlehurst LA; Alsina M; Chen DT; Beg AA; Dalton WS
Cancer Res; 2009 Dec; 69(24):9367-75. PubMed ID: 19934314
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of MMP14 potentiates the therapeutic effect of temozolomide and radiation in gliomas.
Ulasov I; Thaci B; Sarvaiya P; Yi R; Guo D; Auffinger B; Pytel P; Zhang L; Kim CK; Borovjagin A; Dey M; Han Y; Baryshnikov AY; Lesniak MS
Cancer Med; 2013 Aug; 2(4):457-67. PubMed ID: 24156018
[TBL] [Abstract][Full Text] [Related]
16. Enhanced cytotoxic effect of radiation and temozolomide in malignant glioma cells: targeting PI3K-AKT-mTOR signaling, HSP90 and histone deacetylases.
Choi EJ; Cho BJ; Lee DJ; Hwang YH; Chun SH; Kim HH; Kim IA
BMC Cancer; 2014 Jan; 14():17. PubMed ID: 24418474
[TBL] [Abstract][Full Text] [Related]
17. Effect of aberrant p53 function on temozolomide sensitivity of glioma cell lines and brain tumor initiating cells from glioblastoma.
Blough MD; Beauchamp DC; Westgate MR; Kelly JJ; Cairncross JG
J Neurooncol; 2011 Mar; 102(1):1-7. PubMed ID: 20593219
[TBL] [Abstract][Full Text] [Related]
18. Monoketone analogs of curcumin, a new class of Fanconi anemia pathway inhibitors.
Landais I; Hiddingh S; McCarroll M; Yang C; Sun A; Turker MS; Snyder JP; Hoatlin ME
Mol Cancer; 2009 Dec; 8():133. PubMed ID: 20043851
[TBL] [Abstract][Full Text] [Related]
19. Knockdown of Nrf2 enhances autophagy induced by temozolomide in U251 human glioma cell line.
Zhou Y; Wang HD; Zhu L; Cong ZX; Li N; Ji XJ; Pan H; Wang JW; Li WC
Oncol Rep; 2013 Jan; 29(1):394-400. PubMed ID: 23128449
[TBL] [Abstract][Full Text] [Related]
20. TMZ-induced PrPc/par-4 interaction promotes the survival of human glioma cells.
Zhuang D; Liu Y; Mao Y; Gao L; Zhang H; Luan S; Huang F; Li Q
Int J Cancer; 2012 Jan; 130(2):309-18. PubMed ID: 21328340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
